Droplex PIK3CA Mutation Test
Detection of the 11 defined mutations within the catalytic a-subunit of the PI3K gene
Features
Breast Cancer (BC) is the most common cancer in women and is a second leading cause of death in Women. ER+ and HER2- type tumor accounts for about 71 % of all Breast cancer patients, and, 40 % of those BC patients have PIK3CA mutations. When a patient has PIK3CA mutation, they are likely to be resistant to the chemotherapy. Therefore, knowing the existence of PIK3CA mutation is important in treating breast cancer patients with appropriate drugs. The CE-IVD certified Droplex PIK3CA Mutation Test detects 11 defined mutations within the catalytic a-subunit of the PI3K gene using Digital DropletTM Technology as a companion diagnostic.
BIOTYPE is the exclusive distributor of the Droplex Test Series in Germany. Legal manufacturer of the kits is GENCURIX, Inc.
Biomarkers
Exon 7: C420R
Exon 9: E542K, E545K/A/G/D, Q546E/R
Exon 20: H1047R/L/Y
Product specifications
- Cat No.
- CD006
- Cancer type
- Breast Cancer
- Regulatory status
- CE-IVD
- Compatible sample type
- DNA from FFPE tissue, cfDNA from Plasma
- Mutation variants
- 11
- Kit size/reactions
- 24 samples/kit (4 well-reactions/sample)
- Platform
- Digital DropletTM PCR
Resources
Ordering Information
Droplex PIK3CA Mutation Test
Kit size/reactions: 24 samples/kit (4 well-reactions/sample)
Cat.No.: CD006
Status: CE-IVD
Product Request
MODAPLEX
Bench-top system for molecular multi-marker testing
